Join to View Full Profile
4350 Malsbary RdCincinnati, OH 45242
Phone+1 513-751-2273
Fax+1 513-792-5844
Dr. Ward is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified medical oncologist specializing in solid tumor oncology. I am a clinical investigator specializing in cellular therapies for solid tumors. I am the director of clinical research for OHC. I serve on the SCRI executive committees for lung cancer research and immune effector cell research as well as the research advisory board.
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2000 - 2002- Ohio State University HospitalResidency, Internal Medicine, 1997 - 2000
- Ohio State University College of MedicineClass of 1997
Certifications & Licensure
OH State Medical License 1998 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
Clinical Trials
- Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
- A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer Start of enrollment: 2013 Dec 17
Publications & Presentations
PubMed
- A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer.Keith L Knutson, Hala Abu-Fares, Patricia Keating, Matthew S Block, Nadine Norton
Clinical Cancer Research. 2026-01-06 - Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi
Nature Communications. 2025-03-06 - 4 citationsPhase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1-Pretreated Metastatic Non-Small Cell Lung Cancer and Metastatic Cutaneous Melanoma.Sylvia M Lee, Omid Hamid, Robert Jotte, Yousef Zakharia, Theresa Medina
Clinical Cancer Research. 2025-03-03
Press Mentions
Leading-Edge Cancer Therapies Are Saving, Improving Lives in Greater CincinnatiMay 30th, 2025- Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01February 15th, 2024
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
